SYNGENE2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member SYNGENE2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member SYNGENE2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member SYNGENE2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member SYNGENE2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SYNGENE2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SYNGENE2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SYNGENE2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SYNGENE 2022-04-01 2023-03-31 2023-01-06 INR Millions Third quarter Single segment Contract Research and Manufacturing Services 2022-10-01 2022-12-31 Unaudited Standalone 7866000000.00 172000000.00 8038000000.00 2176000000.00 0.00 -114000000.00 2032000000.00 137000000.00 946000000.00 1468000000.00 6645000000.00 1393000000.00 0.00 1393000000.00 332000000.00 -34000000.00 298000000.00 0.00 1095000000.00 0.00 0.00 0.00 0.00 1095000000.00 -57000000.00 1038000000.00 0.00 0.00 4014000000.00 10 2.73 2.71 0.00 0.00 2.73 2.71 Notes: 1. The statement of unaudited standalone and consolidated financial results ( the Statements ) of Syngene International Limited ('the Company') for the quarter and nine months ended 31 December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 23 January 2023. The above Statements have been subjected to limited review by the statutory auditor of the Company. The reports of the statutory auditor are unqualified. The Statements have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. 'The consolidated financial results include the financial results of the Company - Syngene International Limited and the financial result of the following subsidiaries: i. Syngene USA Inc. ii. Syngene Scientific Solutions Limited iii. Syngene Manufacturing Solutions Limited The Company and the Subsidiaries are collectively referred to as 'the Group'. In addition to the above, the standalone and consolidated financial results also include the financial results in respect of Syngene Employees Welfare Trust. 3. 'The Ministry of Commerce and Industry, Government of India issued a Gazatte notification number 29/2015-2020 dated 23 September 2021 on Service Exports from India Scheme (SEIS) for services rendered in financial year 2019 - 2020 with the total entitlement capped at Rs. 50 million per exporter for the period. The Company during the quarter ended 30 September 2021 had reversed the SEIS claim receivables of Rs. 307 million for the financial year 2019-2020 and the same has been presented under Exceptional items in the financial results for the nine months ended 31 December 2021 and for the year ended 31 March 2022. 4. 'The Group operates in a single segment of providing Contract Research and Manufacturing Services. 5. On 27 April 2022, the Board of Directors of the Company have approved an allotment of 638,000 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employee Welfare Trust at face value pursuant to the shareholders’ approval at the Annual General Meeting on 24 July 2019 to allot fresh equity shares upto 1.67% of the paid-up equity capital of the Company in tranches for the purpose of implementation of the Syngene International Limited - Restricted Stock Unit Long Term Incentive Plan FY 2020. 6. 'On 02 August 2022, the Company's Board of Directors approved the acquisition of certain laboratory facilities along with a team of scientists from Biofusion Therapeutics Limited, a fellow subsidiary, through a slump sale of assets and liabilities for a consideration of Rs. 192 million. In accordance with Ind AS 103, Business combinations, the acquisition qualified to be a business combination between entities under common control. Accordingly, acquisition was accounted for at book values with the difference between consideration paid and balances taken over being recorded in reserves. The financial information, in respect of prior periods, as if the business combination had occurred from the beginning of the preceding period in the financial statements have not been restated as the impact was considered to be immaterial. 7. The numbers are aggregated and rounded off in accordance with the prescribed format. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 21991000000.00 481000000.00 22472000000.00 6460000000.00 0.00 -796000000.00 5838000000.00 348000000.00 2710000000.00 4310000000.00 18870000000.00 3602000000.00 0.00 3602000000.00 753000000.00 9000000.00 762000000.00 0.00 2840000000.00 0.00 0.00 0.00 0.00 2840000000.00 -1474000000.00 1366000000.00 0.00 0.00 4014000000.00 10 7.08 7.03 0.00 0.00 7.08 7.03 Foreign exchange fluctuation {gain)/loss, net 156000000.00 Other expenses 1312000000.00 Foreign exchange fluctuation {gain)/loss, net 376000000.00 Other expenses 3934000000.00